Application of long-chain non-coding RNA and inhibitor thereof in prevention and treatment of breast cancer

A long-chain non-coding, breast cancer technology, applied in the field of tumor molecular biology, can solve the problems of patients not receiving effective treatment, tumor cells resurgence, low treatment effect, etc., and achieve synergistic treatment effect and targeted Effects of treatment, improved survival and survival

Active Publication Date: 2021-08-03
SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chemotherapy resistance is an important reason for the resurgence of tumor cells, resulting in recurrence and metastasis, leading to treatment failure and tumor progression
At present, platinum-based drugs are one of the commonly used chemotherapeutic drugs for triple-negative breast cancer in clinical practice. Therefo

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of long-chain non-coding RNA and inhibitor thereof in prevention and treatment of breast cancer
  • Application of long-chain non-coding RNA and inhibitor thereof in prevention and treatment of breast cancer
  • Application of long-chain non-coding RNA and inhibitor thereof in prevention and treatment of breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Acquisition and analysis of long non-coding RNA LINC01778 V2

[0038] 1. Screening of long non-coding RNA LINC01778 V2

[0039] Use cisplatin drug for induction to establish a triple-negative breast cancer stable cell line resistant to cisplatin drug. In this example, the concentration gradient method is used to start from a low concentration. After two years, completely resistant to cisplatin is established. Stable drug-resistant cell lines of triple-negative breast cancer. Then, through lncRNA chip detection, compare cisplatin-resistant triple-negative breast cancer cell lines and cisplatin-sensitive triple-negative breast cancer cell lines, and screen out a batch of differentially expressed lncRNAs; Cisplatin is not resistant to drugs; specifically, BGI sequencing is used to accurately screen lncRNA high-throughput sequencing based on Illumina's fourth-generation high-throughput sequencing platform. lncRNA high-throughput sequencing includes lncRNA identification, l...

Embodiment 2

[0061] Based on the MDA-MB-231 cell line, the activity changes of cisplatin-resistant / cisplatin-sensitive triple-negative breast cancer cells under the action of cisplatin were detected, and the cisplatin-resistant / cisplatin-sensitive triple negative breast cancer cells were detected by fluorescence quantitative PCR (qPCR). Expression of LINC01778 V2 in Negative Breast Cancer Cells

[0062] 1. Detection of activity changes of cisplatin-resistant / cisplatin-sensitive triple-negative breast cancer cells under the action of cisplatin

[0063] The cisplatin-resistant triple-negative breast cancer cell line was MDA-MB-231CisR, and the cisplatin-sensitive triple-negative breast cancer cell line was MDA-MB-231parental. The same dose of cisplatin was administered at the same time, and MDA was observed within 2 days. -Cell activity changes of MB-231CisR and MDA-MB-231parental, results as Figure 5 As shown in (left), the activity of MDA-MB-231CisR cells generally remained elevated with...

Embodiment 3

[0076] Based on the MDA-MB-468 cell line, the activity changes of cisplatin-resistant / cisplatin-sensitive triple-negative breast cancer cells under the action of cisplatin were detected, and the cisplatin-resistant / cisplatin-sensitive triple negative breast cancer cells were detected by fluorescence quantitative PCR (qPCR). Expression of LINC01778 V2 in Negative Breast Cancer Cells

[0077] 1. Detection of activity changes of cisplatin-resistant / cisplatin-sensitive triple-negative breast cancer cells under the action of cisplatin

[0078] The cisplatin-resistant triple-negative breast cancer cell line was MDA-MB-468CisR, and the cisplatin-sensitive triple-negative breast cancer cell line was MDA-MB-468parental. The same dose of cisplatin was administered at the same time, and MDA was observed within 2 days. -Cell activity changes of MB-468CisR and MDA-MB-468parental, results as Image 6 As shown in (left), the activity of MDA-MB-468CisR cells generally remained elevated withi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of long-chain non-coding RNA and an inhibitor of the long-chain non-coding RNA in prevention and treatment of breast cancer, a full-length sequence of the long-chain non-coding RNA LINC01778V2 is cloned for the first time, and the long-chain non-coding RNA LINC01778V2 is differentially expressed in cis-platinum drug-resistant breast cancer and cis-platinum sensitive breast cancer. Therefore, by detecting the LINC01778V2, the diagnosis of the cis-platinum drug resistance of the breast cancer can be realized. Meanwhile, the LINC01778V2 corresponding expression inhibitor can inhibit proliferation of breast cancer tumor cells, promote apoptosis of the breast cancer tumor cells, kill the tumor cells and reverse cisplatin resistance of cisplatin-resistant triple negative breast cancer. The invention also discloses application of the corresponding inhibitor in prevention and treatment of the triple negative breast cancer with cis-platinum resistance.

Description

technical field [0001] The present invention relates to the field of tumor molecular biology, more specifically, relates to the application of a long-chain non-coding RNA and its inhibitor in the prevention and treatment of breast cancer. Background technique [0002] Breast cancer is one of the most common malignant tumors in women. According to data from GLOBOCAN in 2018 and the China Cancer Registry Center in 2019, breast cancer is the most common female malignant tumor in the world and in my country, seriously affecting women's lives and health. In clinical practice, breast cancer can be divided into four different categories according to whether the estrogen / progesterone receptor (ER / PR) of breast cancer cells is positive, whether human epidermal growth factor receptor 2 (HER2) is overexpressed, and the percentage of Ki67. Molecular subtype: Luminal A type, Luminal B type, HER2 overexpression type, triple negative type (TNBC). Different types of breast cancer have diff...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6886A61K31/713A61K45/00A61P35/00
CPCC12Q1/6886A61K31/713A61K45/00A61P35/00C12Q2600/158C12Q2600/178
Inventor 姚燕丹李舜颖黄松音
Owner SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap